These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10466430)
21. Reporter gene regulation in Saccharomyces cerevisiae by the human p53 tumor suppressor protein. Bitter GA; Schaeffer TN; Ellison AR J Mol Microbiol Biotechnol; 2002 Nov; 4(6):539-50. PubMed ID: 12432954 [TBL] [Abstract][Full Text] [Related]
22. Mutational analysis of p53 in human tumors: immunocytochemistry. Slade N; Moll UM Methods Mol Biol; 2003; 234():231-43. PubMed ID: 12824536 [TBL] [Abstract][Full Text] [Related]
23. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573 [TBL] [Abstract][Full Text] [Related]
24. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393 [TBL] [Abstract][Full Text] [Related]
25. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302 [TBL] [Abstract][Full Text] [Related]
26. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions. Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040 [TBL] [Abstract][Full Text] [Related]
27. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Liu Y; Bodmer WF Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264 [TBL] [Abstract][Full Text] [Related]
28. The value of rapid functional assays of germline p53 status in LFS and LFL families. Camplejohn RS; Sodha N; Gilchrist R; Lomax ME; Duddy PM; Miner C; Alarcon-Gonzalez P; Barnes DM; Eeles RA Br J Cancer; 2000 Mar; 82(6):1145-8. PubMed ID: 10735497 [TBL] [Abstract][Full Text] [Related]
29. Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the FASAY (functional analysis of separated alleles in yeast). Paget V; Lechevrel M; Sichel F Mutat Res; 2008 Mar; 652(1):12-9. PubMed ID: 18242117 [TBL] [Abstract][Full Text] [Related]
30. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry. Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868 [TBL] [Abstract][Full Text] [Related]
31. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609 [TBL] [Abstract][Full Text] [Related]
32. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations. Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422 [TBL] [Abstract][Full Text] [Related]
33. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125 [TBL] [Abstract][Full Text] [Related]
34. [The mutational spectra of gene p53 in different types of tumors]. Glazko GV; Rogozin IB; Sozinov AA Tsitol Genet; 1999; 33(3):14-20. PubMed ID: 10474858 [TBL] [Abstract][Full Text] [Related]
35. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Varley JM; Attwooll C; White G; McGown G; Thorncroft M; Kelsey AM; Greaves M; Boyle J; Birch JM Oncogene; 2001 May; 20(21):2647-54. PubMed ID: 11420676 [TBL] [Abstract][Full Text] [Related]
36. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Inga A; Monti P; Fronza G; Darden T; Resnick MA Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981 [TBL] [Abstract][Full Text] [Related]
37. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene. Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735 [TBL] [Abstract][Full Text] [Related]
38. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410 [TBL] [Abstract][Full Text] [Related]
39. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367 [TBL] [Abstract][Full Text] [Related]
40. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]